We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+20.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$41.5M
(+24%)
Cap. Flow
+$31.8M
Cap. Flow
% of AUM
14.78%
Top 10 Holdings %
Top 10 Hldgs %
55.52%
Holding
68
New
22
Increased
11
Reduced
19
Closed
11
Avg Time Held Equity + Options
0.2
years
Top 10 Avg Time Held Equity + Options
0.1
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCP
Quality Care Properties, Inc.
QCP
|
+$11.7M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$10.2M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$8.59M |
| 4 |
GSK
GSK
|
+$8.44M |
| 5 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$6.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Biopharma Inc
ARRY
|
+$14.1M |
| 2 |
eHealth
EHTH
|
+$4.18M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$4.01M |
| 4 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$2.62M |
| 5 |
Puma Biotechnology
PBYI
|
+$2.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 75.31% |
| 2 | Real Estate | 9.99% |
| 3 | Miscellaneous | 7.87% |
| 4 | Industrials | 6.33% |
| 5 | Financials | 0.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Neurogene
NGNE
$466M
| $450K | 0.21% |
1,599
+599
| +60% | +$165K |
2017 Q4
1 quarter
|
|
|
ISEE
52
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $409K | 0.19% |
149,100
| – | – |
2017 Q4
1 quarter
|
|
|
EVHC
53
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $366K | 0.17% |
9,520
-70,000
| -88% | -$2.62M |
2017 Q4
1 quarter
|
|
54
CALL
MiMedx Group
MDXG
$667M
| $335K | 0.16% |
+48,000
| New | +$559K |
2018 Q1
0 quarters
|
|
|
SPNE
55
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $313K | 0.15% |
30,899
| – | – |
2017 Q4
1 quarter
|
|
56
DELISTED
Dermira, Inc.
DERM
| $160K | 0.07% |
+20,018
| New | +$436K |
2018 Q1
0 quarters
|
|
|
QTNT
57
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $49.5K | 0.02% |
263
| – | – |
2017 Q4
1 quarter
|
|
58
Axogen
AXGN
$2.06B
| – | – |
-57,723
| Closed | -$1.63M | – |
|
59
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-2,500
| Closed | -$340K | – |
|
60
Pacira BioSciences
PCRX
$1.45B
| – | – |
-25,100
| Closed | -$1.15M | – |
|
61
Varex Imaging
VREX
$783M
| – | – |
-20,700
| Closed | -$832K | – |
|
62
Zimmer Biomet
ZBH
$18.1B
| – | – |
-14,420
| Closed | -$1.69M | – |
|
|
CLVS
63
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-16,397
| Closed | -$1.11M | – |
|
|
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-1,675
| Closed | -$250K | – |
|
|
ALXN
65
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-33,500
| Closed | -$4.01M | – |
|
66
DELISTED
Civitas Solutions, Inc.
CIVI
| – | – |
-23,529
| Closed | -$402K | – |
|
|
ARDM
67
DELISTED
Aradigm Corp Common Stock
ARDM
| – | – |
-52,115
| Closed | -$349K | – |
|
|
IVTY
68
DELISTED
Invuity, Inc
IVTY
| – | – |
-45,000
| Closed | -$279K | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q1 2018 Portfolio in Review
As of Q1 2018, Eversept Partners held 68 positions worth $215M, up 24% from $174M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Eversept Partners deployed $31.8M of net new capital in Q1 2018, opening 22 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier, followed by Real Estate and Miscellaneous.
On the sell side, the largest reduction was Array Biopharma Inc, an estimated $14.1M trimmed.
- Eversept Partners's largest Q1 2018 buy was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
- Eversept Partners added most to Quality Care Properties, Inc. in Q1 2018, an estimated $11.7M increase.
- Eversept Partners's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $14.1M.
- Eversept Partners fully exited Alexion Pharmaceuticals in Q1 2018, selling an estimated $4.01M.
- Eversept Partners's ten largest holdings make up 56% of its $215M portfolio in Q1 2018.
- Eversept Partners opened 22 new positions and closed 11 in Q1 2018.
- Eversept Partners's portfolio value rose 24% quarter-over-quarter to $215M.
Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.